Tele: 561.316.3330
Breaking Medical Device News

Saturday, October 16, 2021
HomeCLINICAL TRIALS, STUDIES, DATAResults of a Longitudinal Outcome-Based Study: Bronchiectasis Exacerbations Significantly Reduced with HFCWO...

Results of a Longitudinal Outcome-Based Study: Bronchiectasis Exacerbations Significantly Reduced with HFCWO Therapy


Global $45 Billion Endoscopy Market Insights & Forecasts to 2025

The global endoscopy market is predicted to reach US$45.28 billion in 2025, growing, at a CAGR of 7.50%, for the duration spanning 2021-2025.

Global Remote Monitoring Devices Market Research Report (2021 to 2026)

Global Remote Monitoring Devices Market size was estimated at USD 1,035.35 million in 2020, is expected to reach USD 1,170.22 million in 2021.

Research Efforts Fuel the Future of Global Obstructive Lung Disease Management Markets –

The "Global Obstructive Lung Disease Management Research Report" report has been added.

Global Electrophysiology Market (2021 to 2026) – Growth, Trends , COVID-19 Impact and Forecasts –

The Electrophysiology Market is expected to register a CAGR of 8.5% during the forecast period.

Electromed, Inc. (NYSE American:ELMD) today announced the results of a longitudinal outcome-based study published in Respiratory Therapy: The Journal of Pulmonary Technique.

The company reports the longitudinal study shows that high frequency chest wall oscillation (“HFCWO”) therapy with the SmartVest® Airway Clearance System significantly reduces bronchiectasis-related exacerbations including the need for antibiotics, emergency department visits and hospitalizations, and that this effectiveness was maintained for 2.5 years after the initiation of treatment.

Bronchiectasis is an irreversible, chronic lung condition characterized by enlarged and permanently damaged bronchi. The condition is associated with recurrent lower respiratory infections, inflammation, reduction in pulmonary function, impaired respiratory secretion clearance, increased hospitalizations and medication use, and increased morbidity and mortality.1-3 The goals of bronchiectasis treatment are to mobilize airway secretions to reduce respiratory infections, minimize exacerbations, enhance ventilation, and improve a person’s quality of life.4,5

A previously published clinical outcomes study of fifty-nine SmartVest patients with non-cystic fibrosis bronchiectasis (“NCFB”) served as the basis for the longitudinal study.4 This longitudinal study demonstrated that use of HFCWO therapy with the SmartVest system after 2.5 years was associated with a significant reduction in the incidence of bronchiectasis-related exacerbations; 42% decrease in hospitalizations, 38% fewer antibiotic prescriptions, and a 75% decrease in emergency department visits. The study also found that 68% of the patients reported a significant increase in their quality of life. These findings indicate the long-term benefit and clinical utility of HFCWO therapy to reduce bronchiectasis-related exacerbations in patients with NCFB.

Kathleen Skarvan, President and CEO of Electromed reported, “This longitudinal study builds on previously published evidence and demonstrates that improved outcomes for bronchiectasis patients can be sustained 2.5 years after starting SmartVest treatment.” She concluded, “This is the first study of its kind, a longitudinal bronchiectasis outcomes-based study for HFCWO therapy, and these results continue to demonstrate the considerable potential of HFCWO to improve outcomes and quality of life in this population.”

The SmartVest system uses HFCWO, a clinically proven therapy that helps clear the lungs of excess secretions, thereby reducing the risk of respiratory infections and hospitalizations. HFCWO delivers alternating pulses of air into a vest garment that rapidly compresses and releases the chest wall, resulting in an oscillation in airflow within the airways that acts to loosen, thin, and propel mucus toward the major airways where it can be expectorated.


[1] King PT et al. COPD. 2005;2(1):27-34.

[2] Alzeer AH et al. BMC Pulm Med. 2007; 7:17.

[3] Seitz AE et al. Chest. 2010;138(4):944-949.

[4] Sievert CE et al. Respiratory Therapy Journal. 2016;11(4): 34–38.

[5] Sievert CE et al. Respiratory Therapy Journal. 2017;12(1): 45–49.



AMRA Medical’s Whole-body MRI Analysis Used in FSHD Clinical Trial Research Network Study for Biomarker Development

To date, the MOVE study has used functional tests as primary outcomes, but recent studies have shown the promise of MRI for FSHD.

Aethlon Medical Announces Peer-Reviewed Publication of Two Case Studies of Critically Ill COVID-19 Patients Treated with the Hemopurifier®

The publication documents two critically ill COVID-19 patients receiving a combined total of nine, six-hour Hemopurifier® treatment sessions.

Koya Medical Presents Positive Interim Data from Randomized Trial Comparing its Dayspring Lymphedema Treatment to Pneumatic Compression

For people with lymphedema, movement is important from both a clinical perspective and a quality-of-life perspective. These data illustrate the Dayspring treatment’s ability to provide that essential movement while still delivering the clinical outcomes we need from compression therapy.

18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA

“We have observed minimal slow-flow phenomena, seen with other paclitaxel drug-eluting balloons.  We have observed several cases of fast wound healing with SELUTION SLR. It is easy to track and deliver. We are looking forward to gaining further clinical experience with this device,” commented Prof. Chong.

Our Sister Publication: Biotechnology News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy